JNJ Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 15.24% compared to Johnson & Johnson's net margin of 23.56%. Johnson & Johnson's return on equity of 19.98% beat Gilead Sciences's return on equity of 2.5%.

Johnson & Johnson has a consensus price target of $169.07, signalling upside risk potential of 3.84%. On the other hand Gilead Sciences has an analysts' consensus of $111.26 which suggests that it could fall by -0.16%. Given that Johnson & Johnson has higher upside potential than Gilead Sciences, analysts believe Johnson & Johnson is more attractive than Gilead Sciences.

Johnson & Johnson has a beta of 0.473, which suggesting that the stock is 52.686% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.213, suggesting its less volatile than the S&P 500 by 78.702%.

Johnson & Johnson has a quarterly dividend of $1.24 per share corresponding to a yield of 3.05%. Gilead Sciences offers a yield of 2.78% to investors and pays a quarterly dividend of $0.79 per share. Johnson & Johnson pays 84.05% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

Johnson & Johnson quarterly revenues are $22.5B, which are larger than Gilead Sciences quarterly revenues of $7.6B. Johnson & Johnson's net income of $3.4B is higher than Gilead Sciences's net income of $1.8B. Notably, Johnson & Johnson's price-to-earnings ratio is 28.12x while Gilead Sciences's PE ratio is 301.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 4.45x versus 4.87x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Intra-Cellular Therapies has a net margin of 15.24% compared to Johnson & Johnson's net margin of -8.48%. Johnson & Johnson's return on equity of 19.98% beat Intra-Cellular Therapies's return on equity of -8.07%.

Johnson & Johnson has a consensus price target of $169.07, signalling upside risk potential of 3.84%. On the other hand Intra-Cellular Therapies has an analysts' consensus of $132.00 which suggests that it could grow by 0.56%. Given that Johnson & Johnson has higher upside potential than Intra-Cellular Therapies, analysts believe Johnson & Johnson is more attractive than Intra-Cellular Therapies.

Johnson & Johnson has a beta of 0.473, which suggesting that the stock is 52.686% less volatile than S&P 500. In comparison Intra-Cellular Therapies has a beta of 0.695, suggesting its less volatile than the S&P 500 by 30.512%.

Johnson & Johnson has a quarterly dividend of $1.24 per share corresponding to a yield of 3.05%. Intra-Cellular Therapies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Johnson & Johnson pays 84.05% of its earnings as a dividend. Intra-Cellular Therapies pays out -- of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $22.5B, which are larger than Intra-Cellular Therapies quarterly revenues of $199.2M. Johnson & Johnson's net income of $3.4B is higher than Intra-Cellular Therapies's net income of -$16.9M. Notably, Johnson & Johnson's price-to-earnings ratio is 28.12x while Intra-Cellular Therapies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 4.45x versus 19.89x for Intra-Cellular Therapies. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 15.24% compared to Johnson & Johnson's net margin of 32.59%. Johnson & Johnson's return on equity of 19.98% beat Eli Lilly and's return on equity of 80.24%.

Johnson & Johnson has a consensus price target of $169.07, signalling upside risk potential of 3.84%. On the other hand Eli Lilly and has an analysts' consensus of $1,006.63 which suggests that it could grow by 23.74%. Given that Eli Lilly and has higher upside potential than Johnson & Johnson, analysts believe Eli Lilly and is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.473, which suggesting that the stock is 52.686% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

Johnson & Johnson has a quarterly dividend of $1.24 per share corresponding to a yield of 3.05%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Johnson & Johnson pays 84.05% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $22.5B, which are larger than Eli Lilly and quarterly revenues of $13.5B. Johnson & Johnson's net income of $3.4B is lower than Eli Lilly and's net income of $4.4B. Notably, Johnson & Johnson's price-to-earnings ratio is 28.12x while Eli Lilly and's PE ratio is 69.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 4.45x versus 16.33x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 15.24% compared to Johnson & Johnson's net margin of -117.16%. Johnson & Johnson's return on equity of 19.98% beat Moderna's return on equity of -29.09%.

Johnson & Johnson has a consensus price target of $169.07, signalling upside risk potential of 3.84%. On the other hand Moderna has an analysts' consensus of $54.40 which suggests that it could grow by 57.13%. Given that Moderna has higher upside potential than Johnson & Johnson, analysts believe Moderna is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.473, which suggesting that the stock is 52.686% less volatile than S&P 500. In comparison Moderna has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.269%.

Johnson & Johnson has a quarterly dividend of $1.24 per share corresponding to a yield of 3.05%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Johnson & Johnson pays 84.05% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $22.5B, which are larger than Moderna quarterly revenues of $956M. Johnson & Johnson's net income of $3.4B is higher than Moderna's net income of -$1.1B. Notably, Johnson & Johnson's price-to-earnings ratio is 28.12x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 4.45x versus 4.20x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.